Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02XAX
|
||||
Former ID |
DIB020287
|
||||
Drug Name |
LY86057
|
||||
Synonyms |
LY-86057; LY 86057
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [539148] | ||
Structure |
Download2D MOL |
||||
Formula |
C20H26N2O3
|
||||
InChI |
InChI=1S/C20H26N2O3/c1-11(23)12(2)25-20(24)14-7-16-15-5-4-6-17-19(15)13(9-21-17)8-18(16)22(3)10-14/h4-6,9,11-12,14,16,18,21,23H,7-8,10H2,1-3H3
|
||||
InChIKey |
GOHDSZGHAHFEHG-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine 2B receptor | Target Info | Antagonist | [534042] | |
5-hydroxytryptamine 2A receptor | Target Info | Antagonist | [533905] | ||
WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling | |||||
SIDS Susceptibility Pathways | |||||
GPCR downstream signaling | |||||
GPCRs, Other | |||||
References | |||||
Ref 533905 | Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol. 1994 Feb;45(2):277-86. | ||||
Ref 534042 | Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.